BACKGROUND AND PURPOSE: Isoflurane, administered before or during cerebral ischemia, has been shown to exhibit neuroprotection in animal models of ischemic stroke. However, the underlying mechanism remains to be elucidated. In the present study, we determined whether isoflurane posttreatment provides neuroprotection after neonatal hypoxia-ischemia (HI) in rats and evaluated the role of the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway in this volatile anesthetic-mediated neuroprotection. METHODS: HI was induced in postnatal day 10 (P10) rat pups by unilateral carotid ligation and 2 hours of hypoxia. For treatment, 2% isoflurane was administered immediately after HI for 1 hour. As pharmacological interventions, the sphingosine-1-phosphate antagonist VPC23019, phosphatidylinositol-3-kinase inhibitor wortmannin, or opioid antagonist naloxone was administered before HI. Isoflurane posttreatment was evaluated for effects on infarct volume at 48 hours after HI and brain atrophy and neurological outcomes at 4 weeks after HI. The expression of phosphorylated Akt and cleaved caspase-3 was determined by Western blotting and immunofluorescence analysis. RESULTS: Isoflurane posttreatment significantly reduced infarct volume at 48 hours after HI. VPC23019 or wortmannin abrogated the neuroprotective effect of isoflurane, whereas naloxone did not inhibit the isoflurane-induced neuroprotection. Isoflurane posttreatment significantly preserved phosphorylated Akt expression and decreased cleaved caspase-3 levels. These effects were reversed by VPC23019 and wortmannin, respectively. Isoflurane also confers long-term neuroprotective effects against brain atrophy and neurological deficits at 4 weeks after HI. CONCLUSIONS: Isoflurane posttreatment provides lasting neuroprotection against hypoxic-ischemic brain injury in neonatal rats. Activation of the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway may play a key role in isoflurane posttreatment-induced neuroprotection.
BACKGROUND AND PURPOSE:Isoflurane, administered before or during cerebral ischemia, has been shown to exhibit neuroprotection in animal models of ischemic stroke. However, the underlying mechanism remains to be elucidated. In the present study, we determined whether isoflurane posttreatment provides neuroprotection after neonatal hypoxia-ischemia (HI) in rats and evaluated the role of the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway in this volatile anesthetic-mediated neuroprotection. METHODS:HI was induced in postnatal day 10 (P10) rat pups by unilateral carotid ligation and 2 hours of hypoxia. For treatment, 2% isoflurane was administered immediately after HI for 1 hour. As pharmacological interventions, the sphingosine-1-phosphate antagonist VPC23019, phosphatidylinositol-3-kinase inhibitor wortmannin, or opioid antagonist naloxone was administered before HI. Isoflurane posttreatment was evaluated for effects on infarct volume at 48 hours after HI and brain atrophy and neurological outcomes at 4 weeks after HI. The expression of phosphorylated Akt and cleaved caspase-3 was determined by Western blotting and immunofluorescence analysis. RESULTS:Isoflurane posttreatment significantly reduced infarct volume at 48 hours after HI. VPC23019 or wortmannin abrogated the neuroprotective effect of isoflurane, whereas naloxone did not inhibit the isoflurane-induced neuroprotection. Isoflurane posttreatment significantly preserved phosphorylated Akt expression and decreased cleaved caspase-3 levels. These effects were reversed by VPC23019 and wortmannin, respectively. Isoflurane also confers long-term neuroprotective effects against brain atrophy and neurological deficits at 4 weeks after HI. CONCLUSIONS:Isoflurane posttreatment provides lasting neuroprotection against hypoxic-ischemic brain injury in neonatal rats. Activation of the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway may play a key role in isoflurane posttreatment-induced neuroprotection.
Authors: M Morales-Ruiz; M J Lee; S Zöllner; J P Gratton; R Scotland; I Shiojima; K Walsh; T Hla; W C Sessa Journal: J Biol Chem Date: 2001-03-06 Impact factor: 5.157
Authors: Xingshun Xu; Chu Chang Chua; Jinping Gao; Kao-Wei Chua; Hong Wang; Ronald C Hamdy; Balvin H L Chua Journal: Brain Res Date: 2008-06-16 Impact factor: 3.252
Authors: B Vanhaesebroeck; S J Leevers; K Ahmadi; J Timms; R Katso; P C Driscoll; R Woscholski; P J Parker; M D Waterfield Journal: Annu Rev Biochem Date: 2001 Impact factor: 23.643
Authors: Dorothee Weihrauch; John G Krolikowski; Martin Bienengraeber; Judy R Kersten; David C Warltier; Paul S Pagel Journal: Anesth Analg Date: 2005-10 Impact factor: 5.108
Authors: Kumlesh K Dev; Florian Mullershausen; Henri Mattes; Rainer R Kuhn; Graeme Bilbe; Daniel Hoyer; Anis Mir Journal: Pharmacol Ther Date: 2007-09-08 Impact factor: 12.310
Authors: Yilin Zhou; Nancy Fathali; Tim Lekic; Robert P Ostrowski; Chunhua Chen; Robert D Martin; Jiping Tang; John H Zhang Journal: Stroke Date: 2010-12-23 Impact factor: 7.914
Authors: Hjalmar R Bouma; Frans G M Kroese; Jan Willem Kok; Fatimeh Talaei; Ate S Boerema; Annika Herwig; Oana Draghiciu; Azuwerus van Buiten; Anne H Epema; Annie van Dam; Arjen M Strijkstra; Robert H Henning Journal: Proc Natl Acad Sci U S A Date: 2011-01-18 Impact factor: 11.205
Authors: Tim Lekic; Damon Klebe; Roy Poblete; Paul R Krafft; William B Rolland; Jiping Tang; John H Zhang Journal: Curr Med Chem Date: 2015 Impact factor: 4.530
Authors: Danielle N Lyons; Hemendra Vekaria; Teresa Macheda; Vikas Bakshi; David K Powell; Brian T Gold; Ai-Ling Lin; Patrick G Sullivan; Adam D Bachstetter Journal: J Neurotrauma Date: 2018-07-02 Impact factor: 5.269